Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study

OBJECTIVETo assess the long-term safety, tolerability, and efficacy of fremanezumab, a fully humanized monoclonal antibody approved for the preventive treatment of migraine. METHODSA 52-week, multicenter, randomized, double-blind, parallel-group study evaluated fremanezumab monthly or quarterly in a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2020-11, Vol.95 (18), p.e2487-e2499
Hauptverfasser:	Goadsby, Peter J., Silberstein, Stephen D., Yeung, Paul P., Cohen, Joshua M., Ning, Xiaoping, Yang, Ronghua, Dodick, David W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Double-Blind Method Female Humans Male Middle Aged Migraine Disorders - drug therapy Time Factors Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!